[Progress due to networking structures. Challenges for the Competence Network Malignant Lymphomas in the Era of Precision Medicine].

about

[Progress due to networking structures. Challenges for the Competence Network Malignant Lymphomas in the Era of Precision Medicine].

Item

http://www.wikidata.org/entity/Q53149213

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

[Progress due to networking st ...... he Era of Precision Medicine].

@en

[Progress due to networking st ...... he Era of Precision Medicine].

@nl

type

Item

label

[Progress due to networking st ...... he Era of Precision Medicine].

@en

[Progress due to networking st ...... he Era of Precision Medicine].

@nl

prefLabel

[Progress due to networking st ...... he Era of Precision Medicine].

@en

[Progress due to networking st ...... he Era of Precision Medicine].

@nl

P1476

[Progress due to networking st ...... he Era of Precision Medicine].

@en

P2093

Birgit Fath

http://www.w3.org/2001/XMLSchema#string

Natalie Schreiber

http://www.w3.org/2001/XMLSchema#string

Silke Hellmich

http://www.w3.org/2001/XMLSchema#string

P2860

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Treatment of older patients with mantle-cell lymphoma.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

Mutations driving CLL and their evolution in progression and relapse.

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

P2888

s00103-016-2316-9

P304

454-464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00103-016-2316-9

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hallek

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26979715

http://www.w3.org/2001/XMLSchema#string